Dr. Stamler is now the boss in clinical development with his team. All of them came from Teva and this team got deutetrabenazine proved. Now there is also Dr. Sinclair sitting on the board with his understanding of sirtuins and mitochondria (NAD+). All that Dr. Bush has done is important but more important is now to get PBT434 phase II started. We all know ( at least I belive this) that PBT434 is not a normal iron chelator as deferiprone, It is more like mdivi-1 (??), a mitochondrion division inhibitor. I think it is important to notice, that there has not been a single paper published since the first and only PBT434 paper ( almost 2.5 y ago). My understanding is that there is also need to get some papers written. More animal experiments have been done but nothing published in journals, only in congresses. These are needed IMO for the FDA. The new understanding how PBT434 could help neurons in PD and MSA needs to get more data even on the mitochondria level.
ATH Price at posting:
2.4¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)